The FDA continues to update its list of off-patent, off-exclusivity drugs without approved generic competitors to meet the organization's broader goals defined under the Drug Competition Action Plan.
On June 26, 2018, the FDA updated its list of off-patent, off-exclusivity drugs without approved generic competitors to include new drug products and an appendix that identifies new drug application (NDA) products that were removed from the list because one or more abbreviated new drug applications (ANDAs) referencing such NDA drug products have been approved since the previous list publication.
The FDA maintains the list to encourage the development and submission of generic drug ANDAs in markets with little competition and improve transparency. The appendix now lists 11 drugs that previously did not have an approved generic despite the expiry of the reference product’s patents and exclusivity.
There are 2 parts of the list, one listing drugs for which FDA could immediately accept an ANDA without prior discussion, and another that lists drugs with potential legal, regulatory, or scientific issues that would need to be addressed before an ANDA submission. Part 2 includes biological products that are subject to the transition provisions described in the Biologics Price Competition and Innovation Act of 2009.
The list excludes any NDA drugs that have been approved within the past year because it generally is too soon for an ANDA referencing such a product to have been approved, according to an FDA statement.
The FDA first published the list in June 2017 as part of FDA Commissioner Scott Gottlieb’s push to bring more price competition to the market and eliminate a backlog of generic drug applications. The list was updated in December 2017, and added new drugs and reorganized the list based on drug product rather than active ingredients. Additionally, the agency added information about the dosage form for each drug. FDA will update the list every 6 months.
The publication and updating of the list of off-patent, off-exclusivity drugs without approved generic competitors is one step in Commissioner Gottlieb’s Drug Competition Action Plan, which is designed to address what he sees as delays in the approvals of generic drugs by some drug makers who seek to “game” the regulatory system.
According to Rachel Schwartz, director of communications for the Association for Accessible Medicines, the main barrier to developing generics for these products is manufacturing related, as more complex products “require specialty manufacturing processes and facilities” that many generic drug manufacturers do not currently possess.
Health Canada Approves First Omalizumab Biosimilar
December 16th 2024Health Canada has approved Omlyclo, the first omalizumab biosimilar in Canada, for the treatment of chronic idiopathic urticaria, allergic asthma, and chronic rhinosinusitis with nasal polyps, based on a phase 3 study confirming its bioequivalence to the reference product.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Commercial Payer Coverage of Biosimilars: Market Share, Pricing, and Policy Shifts
December 4th 2024Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, revealing growing payer interest in multiple product options, alongside the increasing market share of biosimilars, which contributed to notable reductions in both average sales prices and wholesale acquisition costs.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
The Rebate War: How Originator Companies Are Fighting Back Against Biosimilars
November 25th 2024Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by increasing rebates and lowering net prices, despite short approval-to-launch timelines for biosimilars.